Socazolimab
- CAS No.
- 2305043-30-3
- Chemical Name:
- Socazolimab
- Synonyms
- Socazolimab;Socazolimab (anti-PD-L1);Research Grade Socazolimab;Research Grade Socazolimab (DHJ70117)
- CBNumber:
- CB010617072
- Molecular Formula:
- Molecular Weight:
- 0
- MDL Number:
- MOL File:
- Mol file
- MSDS File:
- SDS
| form | Liquid |
|---|---|
| color | Colorless to light yellow |
| FDA UNII | 82P4S8Q3FB |
Socazolimab price
| Manufacturer | Product number | Product description | CAS number | Packaging | Price | Updated | Buy |
|---|---|---|---|---|---|---|---|
| ChemScene | CS-0628999 | Socazolimab 98.52% | 2305043-30-3 | 1mg | $271 | 2026-06-04 | Buy |
| ChemScene | CS-0628999 | Socazolimab 98.52% | 2305043-30-3 | 5mg | $704 | 2026-06-04 | Buy |
| ChemScene | CS-0628999 | Socazolimab 98.52% | 2305043-30-3 | 10mg | $1127 | 2026-06-04 | Buy |
| ApexBio Technology | BA6160 | Socazolimab | 2305043-30-3 | 1mg | $225 | 2026-05-06 | Buy |
| ApexBio Technology | BA6160 | Socazolimab | 2305043-30-3 | 5mg | $585 | 2026-05-06 | Buy |
Socazolimab Chemical Properties, Uses, Production
Uses
Socazolimab (ZKAB001) is an anti-PD-L1 monoclonal antibody. Socazolimab has lasting safety and efficacy in the treatment of recurrent or metastatic cervical cancer. Socazolimab also has potential applications in small cell lung cancer, esophageal squamous cell carcinoma (ESCC), advanced urothelial carcinoma and osteosarcoma[1][2][3][4][5].
References
[1] An J, et al. Efficacy and Safety of the Anti-PD-L1 mAb Socazolimab for Recurrent or Metastatic Cervical Cancer: a Phase I Dose-Escalation and Expansion Study. Clin Cancer Res. 2022 Dec 1;28(23):5098-5106. DOI:10.1158/1078-0432.CCR-22-1280
[2] Lu S, et al. 143P Efficacy and safety of the anti-PD-L1 monoclonal antibody Socazolimab in combination with carboplatin and etoposide for extensive-stage small cell lung cancer: Results from the phase Ib clinical trial[J]. Annals of Oncology, 2022, 33: S99.
[3] Li Y, et al. 1207P Neoadjuvant PD-L1 inhibitor (socazolimab) plus chemotherapy in patients with locally advanced esophageal squamous cell carcinoma (ESCC): A multicenter, randomized, double-blind phase II study[J]. Annals of Oncology, 2022, 33: S1101.
[4] Duan R, et al. Phase Ib study of anti-PD-L1 monoclonal antibody socazolimab in combination with nab-paclitaxel as first-line therapy for advanced urothelial carcinoma[J]. 2022.
[5] Zhou Y, et al. First-in-Maintenance Therapy for Localized High-Grade Osteosarcoma: An Open-Label Phase I/II Trial of the Anti-PD-L1 Antibody ZKAB001. Clin Cancer Res. 2023 Feb 16;29(4):764-774. DOI:10.1158/1078-0432.CCR-22-2470
Socazolimab Preparation Products And Raw materials
Raw materials
Preparation Products
Socazolimab Suppliers
| Supplier | Tel | Country | ProdList | Advantage | |
|---|---|---|---|---|---|
| TargetMol Chemicals Inc. | 4008200310 15002144251 | marketing@tsbiochem.com | China | 24951 | 58 |
| Shanghai YuanYe Biotechnology Co., Ltd. | 15026964105 | 2881489226@qq.com | China | 89667 | 60 |
| ShangHai Biochempartner Co.,Ltd | 177-54423994 17754423994 | 2853530910@QQ.com | China | 8000 | 62 |
| Guangzhou Hongyuan Chemical Co.,Ltd | 15817493340 | 981810490@qq.com | China | 1577 | 58 |
| Wuhan Chemstan Biotechnology Co., Ltd. | 027-65317797 15926423062 | 422450190@qq.com | China | 10305 | 58 |
| Beijing Jin Ming Biotechnology Co., Ltd. | 010-60605840 | psaitong@jm-bio.com | China | 27626 | 58 |
| Biolab Reagents | 027-65279366 18108604356 | products@biolabreagent.com | China | 9864 | 58 |
| Shanghai Yifei Biotechnology Co. , Ltd. | 021-65675885 18964387627 | customer_service@efebio.com | China | 11963 | 58 |
| Wuhan Acumen Bio-Technology Co.,ltd | 027-027-16602739303 16602739303 | 673003916@qq.com | China | 4593 | 58 |
| Wanxin Biotechnology (Jiaxing) Co., LTD | 0573-83568680 18057391398 | 3956524501@qq.com | China | 1441 | 58 |
View Latest Price from Socazolimab manufacturers
| Image | Update time | Product | Price | Min. Order | Purity | Supply Ability | Manufacturer | |
|---|---|---|---|---|---|---|---|---|
 |
2026-08-08 | Socazolimab
2305043-30-3
|
$119.00-515.00 | 95.00% | 10g | TargetMol Chemicals Inc. |
-
- Socazolimab
2305043-30-3
- $119.00-515.00
- 95.00%
- TargetMol Chemicals Inc.
